Collaboration and distribution agreement with Thermo Fisher Scientific.
Thermo Fisher Scientific obtains exclusive rights to commercialize Devyser’s post-transplant monitoring…
Devyser´s annual report 2022 has today been published on the company´s website.
The report is available on: https://investors.devyser.com/en/reports-presentations
The financial year…
Devyser, the pioneering leader in diagnostic solutions, launches today its first IVDR-certified product. Devyser Compact is a rapid genetic test for prenatal chromosome testing and the…
“Further strong organic growth was reported for the year and quarter. Efforts to build an international marketing and sales organization are starting to pay off.
I am confident that we…
On Tuesday February 21, at 09:00 CET, Devyser Diagnostics AB will host an online presentation of its Q4 2022 year-end report (which will have been published earlier on February 21, at…
Devyser announces today that, due to the newly-introduced "payback" levy in Italy, the company will make provisions for its costs in Italy for the years 2015-2018 as well as estimated…
"Devyser reports yet another quarter of record sales and strong gross margins. The positive sales and margin trend remains stable.
We are following the strategic plan we launched nearly…
Devyser announces its decision to establish a CLIA lab in Atlanta, Georgia, USA. By operating a CLIA lab, Devyser obtains complete control of the selling process, including reimbursement…
On Thursday November 10, at 08.30 CET, Devyser Diagnostics AB will host an online presentation of its Q3 2022 interim report (which will have been published earlier on November 10, at…
Devyser today announces the appointment of John Murad as Vice President and General Manager for Devyser US. He will be responsible for all Devyser operations in North America. John Murad…
